Cheng-Yu Kuo

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)

Cheng‐Pin Chen, Yi‐Chun Lin, Tsung‐Chia Chen et al. · PLoS ONE · 2020 · 81 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials

Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud et al. · medRxiv · 2020 · 79 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +13

Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in Taiwan

Sung‐Pin Tseng, Sheng‐Fan Wang, Cheng-Yu Kuo et al. · PLoS ONE · 2015 · 41 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Clinical features and prognostic factors of emphysematous urinary tract infection.

Cheng-Yu Kuo, Chun‐Yu Lin, Tun‐Chieh Chen et al. · PubMed · 2009 · 28 citations

Medicine, Internal Medicine, Urology +4

A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)

Cheng‐Pin Chen, Yi‐Chun Lin, Tsung‐Chia Chen et al. · medRxiv · 2020 · 25 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13